Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ondrej Bilek"'
Autor:
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA, MAREK STASTNY
Publikováno v:
Anticancer research. 42(4)
This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens.The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treate
Autor:
Magda Barinova, Bohuslav Melichar, Karolina Hurdalkova, Martin Svaton, Jiri Blazek, Lenka Jakubíková, M. Černovská, Michal Jirousek, Daniel Krejci, Jana Skrickova, Milada Zemanova, J. Krejčí, Petra Zemanova, Michal Hrnčiarik, Ondrej Bilek, Ondrej Fischer, Juraj Kultan
Publikováno v:
Anticancer Research. 40:2209-2217
To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung can
Autor:
Jan Jurica, Jiri Vasina, Lenka Zdrazilova-Dubska, Tomas Kazda, Iveta Selingerová, Alexandr Poprach, Simona Borilova, Ondrej Bilek, Miloš Holánek, Sona Stepankova, Igor Kiss
Publikováno v:
International immunopharmacology. 99
ALK targeting with tyrosine kinase inhibitors (TKIs) is a highly potent treatment option for the therapy of ALK positive non-small cell lung cancer (NSCLC). However, pharmacokinetics of TKIs leads to clinically significant drug interactions, and the